证券代码：300244 证券简称：迪安诊断 编号：2018-001 迪安诊断技术集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （股东大会交流） | | | 参与单位名称及 | 瑞银证券 赵冰 瑞银资管 孙裕文 | | | 人员姓名 | 华夏基金 | 陈国喜 前方基金 盛旸 等人 | | 时间 | 2018 年 1 月 12 | 日星期五 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | 副总经理、董事会秘书：王彦肖 | | | 投资者关系活动 | 1 | 、请介绍公司"服务+产品"商业模式，如何公司如何 | | 主要内容介绍 ...

证券代码：300244 证券简称：迪安诊断 编号：2017-005 浙江迪安诊断技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------|---------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （股东大会交流） | | | 参与单位名称及 | 中欧瑞博 赖灏 壹玖资产 郑森峰 | | | 人员姓名 | 纳兰德 廖云辉 | | | 时间 | 2017 年 11 月 03 | 日星期五 | | 地点 | 公司会议室 | | | | | | | 上市公司接待人 员姓名 | 副总经理、董事会秘书：王彦肖 | | | 投 资 者 关 系 | 1 、据不完全统计， | 2015 年全国实验室近 400 家 ...

证券代码：300244 证券简称：迪安诊断 编号：2019-001 迪安诊断技术集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|----------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （股东大会交流） | | | 参与单位名称及 | 兴聚投资：王晓明、赵枫、蒋凌云 | | | 人员姓名 | 兴全基金：邱晓旭 | | | | 富安达基金：刘云鹏 | | | | 中泰证券：谢木青 | | | | 东方证券：李峰 | | | | 六禾投资：周山人 等 | | | 时间 | 2019 年 9 月 3 | 日星期二 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | BD | 总监：燕智，证券事务 ...

证券代码：300244 证券简称：迪安诊断 编号：2018-002 迪安诊断技术集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------|------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （股东大会交流） | | | 参与单位名称及 | 华宝基金 杨钊 | | | 人员姓名 | 兴全基金 赵梓焜 | | | | 浙商证券 张海涛 | | | | 浙商证券 陈亚天 | | | | 浙商证券 陈琛 等人 | | | 时间 | 2018 年 5 月 17 | 日星期四 | | 地点 | 公司会议室 | | | | | | | 上市公司接待人 员姓名 | 副总经理、董事会秘书：王彦肖 | | | 投资者关系活动 | 1 、请问公司 201 ...

编号：2018-003 证券代码：300244 证券简称：迪安诊断 迪安诊断技术集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （股东大会交流） | | | 参与单位名称及 | | 华泰证券 张雪蓉、郭梁良、王玮嘉、孔垂岩 | | 人员姓名 | | 华安基金 刘畅畅 中欧基金 许文星 | | | | | | | | 兴全基金 吴圣涛 神农投资 王宇美 | | | 光大保德信 黄兴亮 等 | | | 时间 | 2018 年 6 月 21 | 日星期四 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | 副总经理、董事会秘 ...

证券代码：300244 证券简称：迪安诊断 迪安诊断技术集团股份有限公司投资者关系活动记录表 编号：2018-004 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （股东大会交流） | | | 参与单位名称及 | | 国信证券：李文英、马步云、朱寒青、梁佳、张智聪 | | 人员姓名 | 东方证券：王树娟 | | | | 光大保德信：房雷 | | | | 富国基金：孙笑悦 | | | | 万家基金：黄兴亮 | | | | 中国人寿资管：王卫华、丁天宇 | | | | 重阳投资：胡敏 | | | | 安联投资：蒋磊 | | | | 富兰克林邓普顿投资：朱国庆 | | | | 元富投顾：傅恒聿 | | | ...

Financial Performance - The company's revenue for Q3 2022 reached ¥4,876,446,577.16, representing a 37.48% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥547,963,534.76, an 8.37% increase compared to the previous year[5] - The company reported a total revenue of ¥15,629,585,233.35 for the first nine months of 2022, a 67.37% increase year-over-year[14] - The diagnostic services business experienced significant growth, generating revenue of ¥9,875,000,000, a 117% increase year-over-year, excluding COVID-19 related income[14] - Total operating revenue for the third quarter reached ¥15,629,585,233.35, a significant increase from ¥9,338,149,453.42 in the previous year, representing a growth of approximately 67.5%[34] - The company's net profit attributable to shareholders increased to ¥5,832,062,228.80 from ¥3,488,040,081.22, marking a growth of around 67.0%[33] - The net profit for the current period is ¥2,867,805,689.73, a significant increase from ¥1,494,473,167.81 in the previous period, representing an increase of approximately 92%[36] - The total profit for the current period is ¥3,381,811,363.56, compared to ¥1,778,332,747.87 in the previous period, representing an increase of approximately 90%[36] Cash Flow and Liquidity - The company's cash flow from operating activities for the first nine months was ¥52,557,545.83, down 88.90% compared to the previous year[14] - Cash flow from operating activities increased to ¥12,086,152,872.35 from ¥8,766,159,447.67, marking a rise of approximately 38%[41] - The cash and cash equivalents at the end of the period decreased to ¥2,068,752,298.58 from ¥2,109,343,743.81, a decline of about 2%[43] - The company received cash from sales and services amounting to ¥11,891,901,448.05, an increase from ¥8,542,078,411.96, which is a growth of about 39%[41] - The net cash flow from investment activities was negative at -¥657,847,944.90, worsening from -¥304,536,662.65 in the previous period[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥21,074,862,356.43, a 35.15% increase from the end of the previous year[5] - Total assets rose to ¥21,074,862,356.43, up from ¥15,594,035,702.21, which is an increase of approximately 35.0%[33] - Total liabilities increased to ¥10,737,924,012.45 from ¥8,118,148,058.94, representing a growth of about 32.4%[33] - The company reported a decrease in short-term borrowings to ¥1,540,345,726.24 from ¥2,509,595,453.39, indicating a reduction of approximately 38.5%[30] - The total equity attributable to shareholders reached ¥8,328,851,828.52, up from ¥5,841,975,826.13, reflecting an increase of about 42.5%[33] Research and Development - The company's R&D expenses for the first nine months amounted to ¥483,459,215.28, reflecting a 71.58% increase year-over-year[14] - Research and development expenses amounted to 483 million yuan, representing a 72% increase compared to the same period last year[15] - Research and development expenses were ¥483,459,215.28, compared to ¥281,760,860.48 in the same period last year, reflecting an increase of approximately 71.5%[34] Shareholder Information - The first phase of the employee stock ownership plan acquired 714,200 shares through secondary market transactions in January 2022[22] - The first batch of the 2020 restricted stock incentive plan vested for 455 individuals, with a total of 3.4548 million shares at a grant price of 24.585 yuan per share[22] - The actual controller, Chen Haibin, had a cumulative pledge of shares amounting to 9.64% of the total share capital[23] - The top ten shareholders held a combined 66.88% of the company's shares[18] Future Projections - The company plans to achieve a revenue target of ¥15.63 billion in the third year of its five-year strategy, with a projected net profit of ¥2.43 billion[14]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the first half of 2022, representing a year-on-year increase of 15%[2]. - The net profit attributable to shareholders was RMB 300 million, with a growth rate of 20% compared to the same period last year[2]. - The company's revenue for the reporting period reached ¥10,753,138,656.19, representing an increase of 85.68% compared to the same period last year[28]. - Net profit attributable to shareholders was ¥1,879,820,480.52, marking a significant increase of 158.54% year-over-year[28]. - The net profit after deducting non-recurring gains and losses was ¥1,879,203,933.12, which is an increase of 196.22% compared to the previous year[28]. - The basic earnings per share (EPS) increased to ¥3.0269, up 158.29% from ¥1.1719 in the same period last year[28]. - The company reported a net cash flow from operating activities of -¥571,457,409.24, a decrease of 579.17% compared to the previous year[28]. - The company achieved a revenue of 10.753 billion yuan in the first half of 2022, representing a year-on-year growth of 85.68%[50]. - The diagnostic services business generated a total revenue of 6.952 billion yuan, with a significant growth of 154.10% year-on-year; specifically, COVID-19 nucleic acid testing contributed 4.748 billion yuan[54]. Market Expansion and Strategy - The company plans to expand its market presence by opening 50 new independent clinical laboratories (ICLs) by the end of 2022[2]. - The company is exploring strategic acquisitions to enhance its service offerings and expand its market share[2]. - The company aims to enhance market penetration by leveraging its comprehensive technical platform, strong R&D capabilities, flexible service models, and significant cost advantages[44]. - The company is positioned to benefit from national policies promoting the health industry, including the "14th Five-Year Plan" which emphasizes the importance of health[44]. - The company is expanding its product line and market presence in response to the increasing demand for domestic IVD products and the impact of the COVID-19 pandemic[48]. - The company has initiated strategic collaborations with well-known enterprises such as Alibaba Health and Baidu Health to enhance its online and offline integrated medical diagnosis platform[57]. Research and Development - Investment in R&D increased by 30%, totaling RMB 150 million, focusing on new diagnostic technologies and products[2]. - The company has launched three new diagnostic products in the first half of 2022, contributing to a 10% increase in product sales[2]. - R&D expenses for the reporting period reached 289 million yuan, a year-on-year increase of 73.29%[62]. - The company is actively involved in the development of high-tech, high-quality, and high-precision IVD products, supported by government policies encouraging domestic production[48]. - The company has established multiple R&D platforms, including a provincial-level R&D center for molecular diagnostics and a provincial-level enterprise technology center[75]. Operational Efficiency - The company launched a digital diagnosis and patient management system, integrating multiple supply chain systems to improve operational efficiency and reduce costs by over 100 million yuan during the reporting period[58]. - The company expanded its cold chain logistics network in East China by adding 6 new logistics routes, improving last-mile delivery speed by 30%[61]. - The logistics efficiency for 95% of specimens is within 12 hours for intra-provincial and 36 hours for inter-provincial delivery, with 80% of reports delivered within 24 hours[75]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[5]. - The company faces quality control risks, emphasizing the importance of maintaining high diagnostic service quality to ensure customer trust and business growth[112]. - Management risks are highlighted due to rapid expansion, necessitating improvements in management systems and processes to maintain competitive advantages[113]. - The company is addressing policy risks related to healthcare reforms that may compress profit margins and require enhanced service capabilities[114]. Shareholder and Financial Management - The company will not distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company has not engaged in any related party transactions during the reporting period[145]. - The company has no situations where the planned progress or expected benefits were not met during the reporting period[94]. - The company reported a total of ¥106,197.6 million in raised funds, with ¥3,925.64 million utilized during the reporting period, and a cumulative total of ¥46,643.18 million invested[92]. Certifications and Compliance - The company has obtained 50 domestic and international certification and recognition certificates, with test results recognized in over 70 countries and regions[40]. - The company aims to enhance its quality management and compliance through continuous improvement mechanisms, achieving 50 domestic and international certifications, leading the industry[58].

Financial Performance - The company reported a revenue of CNY 4.65 billion for Q1 2022, representing a 62.08% increase compared to CNY 2.87 billion in the same period last year[4] - Net profit attributable to shareholders reached CNY 753.71 million, a 122.62% increase from CNY 338.56 million year-on-year[4] - The net profit excluding non-recurring gains and losses was CNY 747.65 million, up 125.60% from CNY 331.40 million in the previous year[4] - Total operating revenue for the first quarter reached ¥4,648,818,816.20, a significant increase from ¥2,868,272,037.86 in the previous year, representing a growth of approximately 62.1%[27] - Net profit for the quarter was ¥916,645,324.39, compared to ¥412,313,510.21 in the same period last year, reflecting a growth of approximately 122.3%[30] - Total comprehensive income attributable to the parent company was CNY 753,710,562.37, up from CNY 338,559,466.66 in the previous period, representing a growth of approximately 122.3%[33] - Basic earnings per share increased to CNY 1.2148 from CNY 0.5457, reflecting a rise of about 122.3%[33] Cash Flow and Liquidity - The company's cash flow from operating activities was negative at CNY -973.14 million, a decline of 136.81% compared to CNY -410.93 million in the same period last year[4] - Net cash flow from operating activities was negative at CNY -973,140,105.33, compared to CNY -410,932,425.84 in the previous period, indicating a worsening cash flow situation[34] - Cash inflow from operating activities totaled CNY 2,841,260,124.16, an increase from CNY 2,438,043,863.96 year-over-year[34] - Cash outflow for purchasing goods and services was CNY 2,342,881,410.10, up from CNY 1,791,932,468.72, marking a rise of approximately 30.7%[34] - The ending cash and cash equivalents balance was CNY 1,449,166,159.37, down from CNY 1,561,552,524.76, reflecting a decrease of approximately 7.2%[40] Assets and Liabilities - Total assets increased by 12.51% to CNY 17.54 billion compared to CNY 15.59 billion at the end of the previous year[4] - Total liabilities rose to ¥9,118,653,470.41, up from ¥8,118,148,058.94, which is an increase of approximately 12.3%[25] - The total current assets of the company at the end of the reporting period are approximately RMB 12.72 billion, an increase from RMB 10.85 billion at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,710, with the largest shareholder, Chen Haibin, holding 26.38% of shares[12] - The company has pledged 122,744,200 shares held by Chen Haibin, which represents a significant portion of his holdings[12] - The total number of shares held by the top ten shareholders accounts for a substantial portion of the company's equity, with the top shareholder holding over 26%[12] Research and Development - The company’s R&D expenses increased by 52.63% to CNY 115.04 million, reflecting a commitment to enhancing innovation capabilities[8] - Research and development expenses for the quarter were ¥115,038,434.41, compared to ¥75,368,826.63 in the previous year, indicating a year-over-year increase of approximately 52.7%[30] Investment and Financing - The company has successfully completed a loan agreement with the International Finance Corporation (IFC) for up to USD 150 million, enhancing its financial flexibility[17] - The company raised CNY 1,691,368,000.00 in borrowings, an increase from CNY 1,516,795,494.40 in the previous period[40] - The company has engaged in a stock buyback program, purchasing 714,200 shares at an average price of RMB 29.40 per share, totaling approximately RMB 21 million[19] Inventory and Receivables - Accounts receivable increased significantly to approximately RMB 8.35 billion, compared to RMB 6.29 billion at the beginning of the year, indicating a growth of about 32.6%[19] - Inventory at the end of the reporting period is approximately RMB 1.53 billion, up from RMB 1.33 billion, reflecting an increase of about 15.5%[19]

Financial Performance - The company's revenue for Q3 2021 reached ¥3,546,935,832.26, an increase of 18.27% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥505,643,776.08, reflecting a growth of 27.05% year-on-year[4] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥531,233,840.66, up 42.16% from the previous year[4] - The company achieved a total revenue of ¥9,338,149,453.42 for the first nine months of 2021, a 24.97% increase compared to the same period last year[12] - The net profit attributable to shareholders for the first nine months of 2021 was ¥1,232,732,701.26, up 37.07% year-on-year[12] - Net profit for the quarter was ¥1,494,473,167.81, representing a 35% increase from ¥1,107,412,962.29 in the previous year[34] - The net profit attributable to the parent company was CNY 1,232,732,701.26, an increase from CNY 899,354,586.42 in the previous period, representing a growth of approximately 37.1%[37] - The total comprehensive income attributable to the parent company was CNY 1,232,732,701.26, compared to CNY 899,354,586.42 in the previous period, indicating a significant increase[37] Earnings and Shareholder Value - The company's basic earnings per share for Q3 2021 was ¥0.8149, a rise of 27.03% compared to the same period last year[4] - The basic earnings per share rose to CNY 1.9868 from CNY 1.4495, reflecting a growth of about 37%[37] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥15,341,939,927.49, representing a 23.74% increase from the end of the previous year[4] - Total assets reached ¥15,341,939,927.49, up from ¥12,398,749,686.11 year-over-year, reflecting a growth of 23.5%[30] - Total liabilities increased to ¥7,688,668,888.67, compared to ¥6,369,960,305.25 in the previous year, marking a rise of 20.7%[30] - The equity attributable to shareholders of the parent company was CNY 4,697,870,632.84, remaining unchanged from the previous period[51] Cash Flow and Investments - Cash inflows from operating activities totaled CNY 8,766,159,447.67, up from CNY 6,834,924,774.94, marking an increase of approximately 28.4%[40] - Cash outflows from operating activities were CNY 8,292,540,839.98, compared to CNY 6,404,596,463.00 in the previous period, resulting in a net cash flow from operating activities of CNY 473,618,607.69, up from CNY 430,328,311.94[40] - Cash inflows from investing activities were CNY 356,975,604.93, compared to CNY 158,844,631.40 in the previous period, showing a significant increase[42] - Cash inflows from financing activities amounted to CNY 4,486,209,464.19, an increase from CNY 3,537,155,102.96 in the previous period[42] Research and Development - Research and development expenses for Q3 2021 were ¥281,760,860.48, an increase of 41.43% year-on-year, reflecting the company's commitment to its "Leading the Future" strategy[12] - R&D expenses increased to 282 million yuan, a 41% rise compared to the same period last year, focusing on molecular diagnostics, pathology, mass spectrometry, and trace elements[13] Business Segments - The diagnostic services business achieved revenue of 4.556 billion yuan, a year-on-year increase of 23%, with revenue excluding COVID-19 business at 2.916 billion yuan, up 37% year-on-year and 36% compared to 2019[13] - The diagnostic products business generated revenue of 5.291 billion yuan, reflecting a 26% year-on-year growth[13] - The channel agency business saw stable growth, with revenue of 4.904 billion yuan, a 25% increase year-on-year and 21% compared to 2019[13] - The self-produced products business experienced rapid growth, achieving revenue of 387 million yuan, a 51% increase year-on-year[13] Operational Metrics - Operating cash flow improved significantly, with a net increase to 474 million yuan[13] - The company reported a significant increase in accounts receivable, which reached ¥6,084,306,440.79, a growth of 34.31% due to expanded business operations[9] - Accounts receivable rose to approximately 6.084 billion yuan, compared to 4.530 billion yuan at the end of 2020[24] - Inventory increased to approximately 1.324 billion yuan, up from 1.123 billion yuan at the end of 2020[24]